CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Fibrocell Science Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Fibrocell Science Inc
405 Eagleview Blvd
Phone: (484) 713-6000p:484 713-6000 EXTON, PA  19341-1117  United States Ticker: FCSC FCSC

Business Summary
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Douglas J.Swirsky 48 12/16/2016 3/4/2013
President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer John M.Maslowski 43 6/22/2017 6/1/2012
Chief Financial Officer, Secretary, Principal Financial Officer and Principal Accounting Officer Sean D.Buckley 37 8/18/2019 6/19/2018
6 additional Officers and Directors records available in full report.

Business Names
Business Name
FCSC
Fibrocell Science Inc.
Fibrocell Technologies, Inc.
Isolagen International, S.A.

General Information
Number of Employees: 23 (As of 12/31/2016)
Outstanding Shares: 9,758,332 (As of 11/7/2019)
Shareholders: 139
Stock Exchange: NASD
Federal Tax Id: 870458888
Fax Number: (302) 655-5049
Email Address: info@fibrocellscience.com


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, December 12, 2019